Morgan Stanley
NYMX

Morgan Stanley’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Morgan Stanley’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-98,686
Closed -$18.8K – 7847
2023
Q2 		$18.8K Hold
98,686
– – ﹤0.01% 6590
2023
Q1 		$33.6K Buy
98,686
+1,068
+1% +$434 ﹤0.01% 6431
2022
Q4 		$31.6K Buy
97,618
+1,049
+1% +$380 ﹤0.01% 6488
2022
Q3 		$40K Buy
96,569
+30,149
+45% +$12K ﹤0.01% 6509
2022
Q2 		$28K Sell
66,420
-1,854
-3% -$1.71K ﹤0.01% 6861
2022
Q1 		$86K Buy
68,274
+1,174
+2% +$1.81K ﹤0.01% 6411
2021
Q4 		$87K Sell
67,100
-3,517
-5% -$5.61K ﹤0.01% 6524
2021
Q3 		$145K Sell
70,617
-5,622
-7% -$9.96K ﹤0.01% 6173
2021
Q2 		$120K Buy
76,239
+10,471
+16% +$19.4K ﹤0.01% 6273
2021
Q1 		$146K Sell
65,768
-35,979
-35% -$94.8K ﹤0.01% 5828
2020
Q4 		$253K Buy
101,747
+27,596
+37% +$61K ﹤0.01% 5472
2020
Q3 		$182K Sell
74,151
-4,045
-5% -$11.8K ﹤0.01% 5166
2020
Q2 		$277K Buy
78,196
+6,500
+9% +$20.6K ﹤0.01% 4915
2020
Q1 		$168K Buy
71,696
+1,309
+2% +$3.67K ﹤0.01% 4946
2019
Q4 		$155K Buy
70,387
+1,562
+2% +$3.08K ﹤0.01% 5505
2019
Q3 		$126K Sell
68,825
-41,869
-38% -$73.2K ﹤0.01% 5358
2019
Q2 		$160K Buy
110,694
+27,160
+33% +$47.5K ﹤0.01% 5120
2019
Q1 		$165K Sell
83,534
-63,600
-43% -$135K ﹤0.01% 5163
2018
Q4 		$193K Sell
147,134
-2,984
-2% -$5.46K ﹤0.01% 5299
2018
Q3 		$369K Sell
150,118
-5,973
-4% -$17.6K ﹤0.01% 5153
2018
Q2 		$524K Buy
156,091
+38,776
+33% +$149K ﹤0.01% 5068
2018
Q1 		$496K Buy
117,315
+4,987
+4% +$17.3K ﹤0.01% 5006
2017
Q4 		$370K Buy
112,328
+25,037
+29% +$91.3K ﹤0.01% 5137
2017
Q3 		$333K Sell
87,291
-144,681
-62% -$549K ﹤0.01% 5107
2017
Q2 		$1.02M Buy
231,972
+192,576
+489% +$791K ﹤0.01% 4365
2017
Q1 		$144K Buy
39,396
+30,749
+356% +$101K ﹤0.01% 5470
2016
Q4 		$24K Sell
8,647
-19,629
-69% -$60.9K ﹤0.01% 5958
2016
Q3 		$93K Buy
28,276
+21,762
+334% +$71.2K ﹤0.01% 5341
2016
Q2 		$22K Sell
6,514
-3,527
-35% -$8.66K ﹤0.01% 5820
2016
Q1 		$25K Sell
10,041
-308,708
-97% -$730K ﹤0.01% 5856
2015
Q4 		$1.04M Sell
318,749
-226,932
-42% -$761K ﹤0.01% 4015
2015
Q3 		$1.88M Buy
545,681
+538,172
+7,167% +$1.25M ﹤0.01% 3572
2015
Q2 		$10K Buy
7,509
+6,940
+1,220% +$9.7K ﹤0.01% 6300
2015
Q1 		$0 Sell
569
-3,621
-86% -$1.71K ﹤0.01% 6690
2014
Q4 		$1K Sell
4,190
-19,190
-82% -$40.9K ﹤0.01% 6506
2014
Q3 		$101K Sell
23,380
-8,712
-27% -$42.7K ﹤0.01% 5478
2014
Q2 		$159K Buy
32,092
+16,478
+106% +$84.8K ﹤0.01% 5270
2014
Q1 		$86K Buy
15,614
+7,427
+91% +$43.1K ﹤0.01% 5511
2013
Q4 		$50K Sell
8,187
-1,912
-19% -$13K ﹤0.01% 5591
2013
Q3 		$67K Buy
+10,099
New +$66K ﹤0.01% 5160

Other funds holding NYMX

DDC
DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return
FCFC
First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return
CAM
Cubic Asset Management Boston, Massachusetts $422M AUM 29.18% 1-Year Est. Return
ODIJL
One Day In July LLC Burlington, Vermont $1.25B AUM 12.08% 1-Year Est. Return

Morgan Stanley's NYMX Position: Q3 2023 in Review

Morgan Stanley sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2023, closing a stake of 98,686 shares — an estimated $18.8K sold.

Morgan Stanley first reported a position in NYMX in Q3 2013 and held it in 40 quarters. The position peaked at $1.88M in Q3 2015. 5 funds tracked by Wall St. Rank hold NYMX as of Q3 2023.

  • Morgan Stanley reported no remaining Nymox Pharmaceutical Corp position as of Q3 2023 after selling out during the quarter.
  • Morgan Stanley sold 98,686 Nymox Pharmaceutical Corp shares in Q3 2023, an estimated $18.8K.
  • Morgan Stanley first reported a position in Nymox Pharmaceutical Corp in Q3 2013 and held it in 40 quarters.
  • Morgan Stanley's Nymox Pharmaceutical Corp position peaked at $1.88M in Q3 2015.
  • 5 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2023.

Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.